AU7234987A - Viral vector coding for a glycoprotein of the virus responsible for a.i.d.s., vaccine and antibody - Google Patents

Viral vector coding for a glycoprotein of the virus responsible for a.i.d.s., vaccine and antibody

Info

Publication number
AU7234987A
AU7234987A AU72349/87A AU7234987A AU7234987A AU 7234987 A AU7234987 A AU 7234987A AU 72349/87 A AU72349/87 A AU 72349/87A AU 7234987 A AU7234987 A AU 7234987A AU 7234987 A AU7234987 A AU 7234987A
Authority
AU
Australia
Prior art keywords
glycoprotein
viral vector
vaccine
antibody
vector coding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU72349/87A
Other versions
AU604696B2 (en
Inventor
Marc Girard
Marie-Paule Kieny
Jean-Pierre Lecocq
Luc Montagnier
Guy Rautmann
Simon Wain-Hobson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transgene SA
Institut Pasteur de Lille
Original Assignee
Transgene SA
Institut Pasteur de Lille
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26225146&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU7234987(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR8605043A external-priority patent/FR2596771B1/en
Application filed by Transgene SA, Institut Pasteur de Lille filed Critical Transgene SA
Publication of AU7234987A publication Critical patent/AU7234987A/en
Application granted granted Critical
Publication of AU604696B2 publication Critical patent/AU604696B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Viral vector characterized in that it comprises at least a portion of the genome of a virus, a gene coding for one of the glycoproteins (gp) of the envelope of the virus responsible for AIDS, as well as the elements providing for the expression of said glycoprotein in cells.
AU72349/87A 1986-04-08 1987-04-08 Viral vector coding for a glycoprotein of the virus responsible for a.i.d.s., vaccine and antibody Expired AU604696B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR8605043A FR2596771B1 (en) 1986-04-08 1986-04-08 VIRAL VECTOR AND RECOMBINANT DNA ENCODING VIA GLYCOPROTEIN CAUSAL AGENT OF THE S.I.D.A, CELL CULTURE INFECTED WITH THIS VECTOR, PROCESS FOR PREPARING GLYCOPROTEIN, GLYCOPROTEIN OBTAINED, VACCINE AND ANTIBODY OBTAINED
FR8605043 1986-04-08
FR8615106A FR2606029B2 (en) 1986-04-08 1986-10-29 VIRAL VECTOR AND RECOMBINANT DNA ENCODING VIA GLYCOPROTEIN CAUSAL AGENT OF THE S.I.D.A, CELL CULTURE INFECTED WITH THIS VECTOR, PROCESS FOR PREPARING GLYCOPROTEIN, GLYCOPROTEIN OBTAINED, VACCINE AND ANTIBODY OBTAINED
FR8615106 1986-10-29

Publications (2)

Publication Number Publication Date
AU7234987A true AU7234987A (en) 1987-11-09
AU604696B2 AU604696B2 (en) 1991-01-03

Family

ID=26225146

Family Applications (1)

Application Number Title Priority Date Filing Date
AU72349/87A Expired AU604696B2 (en) 1986-04-08 1987-04-08 Viral vector coding for a glycoprotein of the virus responsible for a.i.d.s., vaccine and antibody

Country Status (12)

Country Link
EP (1) EP0245136B1 (en)
JP (3) JP2719917B2 (en)
KR (1) KR960001819B1 (en)
AT (1) ATE103328T1 (en)
AU (1) AU604696B2 (en)
CA (1) CA1341353C (en)
DE (1) DE3789400T2 (en)
DK (1) DK175613B1 (en)
ES (1) ES2052589T3 (en)
FR (1) FR2606029B2 (en)
PT (1) PT84640B (en)
WO (1) WO1987006260A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681713A (en) * 1987-05-08 1997-10-28 Smithkline Beecham Corporation Expression of heterologous proteins in Drosophila cells
US6133029A (en) * 1988-03-21 2000-10-17 Chiron Corporation Replication defective viral vectors for infecting human cells
IL89567A0 (en) * 1988-03-28 1989-09-10 Univ Leland Stanford Junior Mutated hiv envelope protein
US5614404A (en) * 1988-06-10 1997-03-25 Theriod Biologics, Incorporated Self-assembled, defective, non-self-propagating lentivirus particles
US5747324A (en) * 1988-06-10 1998-05-05 Therion Biologics Corporation Self-assembled, defective, non-self-propagating lentivirus particles
AU3775789A (en) * 1988-06-10 1990-01-05 Applied Biotechnology, Inc. A method of evaluating recombinant vaccines against immunodeficiency virus
EP0385909B1 (en) * 1989-03-03 1994-07-13 MicroGeneSys, Inc. A kit or composition for the prevention or treatment of HIV-1 infections
EP0897987B1 (en) * 1989-10-24 2001-02-28 Chiron Corporation Secretion of human protein linked to gamma interferon signal peptide
US5817491A (en) * 1990-09-21 1998-10-06 The Regents Of The University Of California VSV G pseusdotyped retroviral vectors
US6228608B1 (en) * 1991-02-28 2001-05-08 Aquila Biopharmaceuticals, Inc. Recombinant FIV glycoprotein 160 and P24 gag protein
FR2676071B1 (en) * 1991-05-02 1994-11-18 Transgene Sa NEW NON-CLeavABLE, SOLUBLE, HYBRID-FORMING GP160 VARIANT.
GB9215233D0 (en) * 1992-07-17 1992-09-02 Pitman Moore Inc Vaccines
US5888814A (en) * 1994-06-06 1999-03-30 Chiron Corporation Recombinant host cells encoding TNF proteins
FR2766091A1 (en) 1997-07-18 1999-01-22 Transgene Sa ANTITUMOR COMPOSITION BASED ON MODIFIED IMMUNOGENIC POLYPEPTIDE WITH CELL LOCATION
EP1925626A1 (en) 2003-07-21 2008-05-28 Transgene S.A. Novel multifunctional cytokines
CN1304580C (en) * 2004-07-09 2007-03-14 楼伟 Surface glucoprotein gp160 of recombination expression human acquired immunity defact virus 1
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
CN109134640A (en) 2012-10-23 2019-01-04 爱默蕾大学 GM-CSF and IL-4 conjugates, composition and relative method

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA867281B (en) * 1985-09-25 1987-05-27 Oncogen Vaccines and immunoassays for acquired immune deficiency syndrome
EP0243029A1 (en) * 1986-04-08 1987-10-28 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Recombinant vaccinia virus expressing human retrovirus gene

Also Published As

Publication number Publication date
AU604696B2 (en) 1991-01-03
CA1341353C (en) 2002-04-02
EP0245136A1 (en) 1987-11-11
DK641787A (en) 1987-12-07
ES2052589T3 (en) 1994-07-16
JP2719917B2 (en) 1998-02-25
FR2606029A2 (en) 1988-05-06
JPH01500161A (en) 1989-01-26
JPH1059868A (en) 1998-03-03
KR880701283A (en) 1988-07-26
DE3789400D1 (en) 1994-04-28
DK641787D0 (en) 1987-12-07
ATE103328T1 (en) 1994-04-15
DE3789400T2 (en) 1994-09-01
PT84640B (en) 1989-11-30
DK175613B1 (en) 2004-12-27
FR2606029B2 (en) 1989-02-03
JPH08224090A (en) 1996-09-03
EP0245136B1 (en) 1994-03-23
WO1987006260A1 (en) 1987-10-22
JP2743164B2 (en) 1998-04-22
KR960001819B1 (en) 1996-02-05
PT84640A (en) 1987-05-01

Similar Documents

Publication Publication Date Title
AU7234987A (en) Viral vector coding for a glycoprotein of the virus responsible for a.i.d.s., vaccine and antibody
AU1225088A (en) Peptides having immunological properties 2-hiv-2
AU3762889A (en) Hiv-3 retrovirus and its use
AU1138388A (en) Hybrid rna virus
AU3636189A (en) Hiv-2 virus variants
AU580059B2 (en) Vaccine against rabies and preparation process thereof
HK107595A (en) Recombinant herpes simplex gb-gd vaccine
AU7514087A (en) Vaccine containing the protein f of the aids virus
AU7028998A (en) Retroviral vectors, method for the production and the use thereof for gene transfer in cd4-positive cells
MX9707910A (en) Glucose-inducible recombinant viral vector.
DK498387A (en) Viral DNA SEQUENCE
EP0276591A3 (en) Viral vector and recombinant dna coding for the p25 protein of the aids virus
AU2190288A (en) Vector for the expression of proteins of the HIV-2 virus, one of the casual agents of AIDS, cell culture infected or transformed by this vector, proteins obtained, vaccine and antibodies obtained
AU635309B2 (en) Gibbon ape leukemia virus receptor
WO1988007080A3 (en) Transgenic animal cells resistant to viral infection
AP1561A (en) Use of non-cytolytic retrovirus as vaccines for the treatment of HIV infection.
AUPP700798A0 (en) Recombinant viral constructs and methods relating thereto
EP0234862A3 (en) Expression of recombinant proteins in yeast